A safety evaluation trial of TEV-48125 self-administered in migraine patients

A multicenter, open-label trial to evaluate the safety of TEV-48125 when subcutaneously self-administered in migraine patients at the trial site and at home

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225136

Enrollment

Registered

2020-03-19

Start date

2020-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

investigational material(s) Generic name etc : TEV-48125 INN of investigational material : - Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient has a history of migraine (according to The International Classification of Headache Disorders, ICHD)or clinical judgment suggests a migraine diagnosis (not better accounted for by another ICHD diagnosis) for 12 months or over prior to informed consent.

Exclusion criteria

Exclusion criteria: The patient cannot participate or successfully complete the trial for other reasons in the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
safety Occurrence of adverse events	—

Secondary

Measure	Time frame
other Evaluation of the execution status of self-administration at home	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026